1 Study Coverage 1.1 Acute Myeloid Leukemia (AML) Therapeutics Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million) Introduction 1.2 Global Acute Myeloid Leukemia (AML) Therapeutics Outlook 2017 VS 2022 VS 2028 1.2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size for the Year 2017-2028 1.2.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size for the Year 2017-2028 1.3 Acute Myeloid Leukemia (AML) Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States Acute Myeloid Leukemia (AML) Therapeutics in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of Acute Myeloid Leukemia (AML) Therapeutics Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 Acute Myeloid Leukemia (AML) Therapeutics Market Dynamics 1.4.1 Acute Myeloid Leukemia (AML) Therapeutics Industry Trends 1.4.2 Acute Myeloid Leukemia (AML) Therapeutics Market Drivers 1.4.3 Acute Myeloid Leukemia (AML) Therapeutics Market Challenges 1.4.4 Acute Myeloid Leukemia (AML) Therapeutics Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 Acute Myeloid Leukemia (AML) Therapeutics by Type 2.1 Acute Myeloid Leukemia (AML) Therapeutics Market Segment by Type 2.1.1 Chemotherapy 2.1.2 Radiation therapy 2.1.3 Stem Cell Transplant 2.1.4 Targeted Therapy 2.1.5 Others 2.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2017, 2022 & 2028) 2.3 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2017-2028) 2.4 United States Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2017, 2022 & 2028) 2.5 United States Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2017-2028) 3 Acute Myeloid Leukemia (AML) Therapeutics by Application 3.1 Acute Myeloid Leukemia (AML) Therapeutics Market Segment by Application 3.1.1 Hospital 3.1.2 Clinics 3.1.3 Others 3.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2017, 2022 & 2028) 3.3 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2017-2028) 3.4 United States Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2017, 2022 & 2028) 3.5 United States Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2017-2028) 4 Global Acute Myeloid Leukemia (AML) Therapeutics Competitor Landscape by Company 4.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Company 4.1.1 Top Global Acute Myeloid Leukemia (AML) Therapeutics Companies Ranked by Revenue (2021) 4.1.2 Global Acute Myeloid Leukemia (AML) Therapeutics Revenue by Player (2017-2022) 4.2 Global Acute Myeloid Leukemia (AML) Therapeutics Concentration Ratio (CR) 4.2.1 Acute Myeloid Leukemia (AML) Therapeutics Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of Acute Myeloid Leukemia (AML) Therapeutics in 2021 4.2.3 Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Acute Myeloid Leukemia (AML) Therapeutics Headquarters, Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million) Type 4.3.1 Global Acute Myeloid Leukemia (AML) Therapeutics Headquarters and Area Served 4.3.2 Global Acute Myeloid Leukemia (AML) Therapeutics Companies Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into Acute Myeloid Leukemia (AML) Therapeutics Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States Acute Myeloid Leukemia (AML) Therapeutics Market Size by Company 4.5.1 Top Acute Myeloid Leukemia (AML) Therapeutics Players in United States, Ranked by Revenue (2021) 4.5.2 United States Acute Myeloid Leukemia (AML) Therapeutics Revenue by Players (2020, 2021 & 2022) 5 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region 5.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region (2017-2028) 5.2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region: 2017-2022 5.2.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth 2017-2028 6.1.2 North America Acute Myeloid Leukemia (AML) Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth 2017-2028 6.3.2 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth 2017-2028 6.4.2 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 UAE 7 Company Profiles 7.1 Bristol-Myers Squibb 7.1.1 Bristol-Myers Squibb Company Details 7.1.2 Bristol-Myers Squibb Business Overview 7.1.3 Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Introduction 7.1.4 Bristol-Myers Squibb Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) 7.1.5 Bristol-Myers Squibb Recent Development 7.2 Novartis 7.2.1 Novartis Company Details 7.2.2 Novartis Business Overview 7.2.3 Novartis Acute Myeloid Leukemia (AML) Therapeutics Introduction 7.2.4 Novartis Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) 7.2.5 Novartis Recent Development 7.3 Roche 7.3.1 Roche Company Details 7.3.2 Roche Business Overview 7.3.3 Roche Acute Myeloid Leukemia (AML) Therapeutics Introduction 7.3.4 Roche Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) 7.3.5 Roche Recent Development 7.4 Genmab 7.4.1 Genmab Company Details 7.4.2 Genmab Business Overview 7.4.3 Genmab Acute Myeloid Leukemia (AML) Therapeutics Introduction 7.4.4 Genmab Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) 7.4.5 Genmab Recent Development 7.5 GlaxoSmithKline Pharmaceuticals 7.5.1 GlaxoSmithKline Pharmaceuticals Company Details 7.5.2 GlaxoSmithKline Pharmaceuticals Business Overview 7.5.3 GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Introduction 7.5.4 GlaxoSmithKline Pharmaceuticals Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) 7.5.5 GlaxoSmithKline Pharmaceuticals Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. Acute Myeloid Leukemia (AML) Therapeutics Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. Acute Myeloid Leukemia (AML) Therapeutics Market Trends Table 3. Acute Myeloid Leukemia (AML) Therapeutics Market Drivers Table 4. Acute Myeloid Leukemia (AML) Therapeutics Market Challenges Table 5. Acute Myeloid Leukemia (AML) Therapeutics Market Restraints Table 6. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Acute Myeloid Leukemia (AML) Therapeutics Companies in Global Market, Ranking by Revenue (2021) Table 11. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue by Player, (US$ Million), 2017-2022 Table 12. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Share by Player, 2017-2022 Table 13. Global Acute Myeloid Leukemia (AML) Therapeutics Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global Acute Myeloid Leukemia (AML) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia (AML) Therapeutics as of 2021) Table 15. Top Players of Acute Myeloid Leukemia (AML) Therapeutics in Global Market, Headquarters and Area Served Table 16. Companies Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into Acute Myeloid Leukemia (AML) Therapeutics Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top Acute Myeloid Leukemia (AML) Therapeutics Players in United States Market, Ranking by Revenue (2021) Table 20. United States Acute Myeloid Leukemia (AML) Therapeutics Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States Acute Myeloid Leukemia (AML) Therapeutics Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region (2017-2022) & (US$ Million) Table 24. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America Acute Myeloid Leukemia (AML) Therapeutics Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe Acute Myeloid Leukemia (AML) Therapeutics Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa Acute Myeloid Leukemia (AML) Therapeutics Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Bristol-Myers Squibb Company Details Table 31. Bristol-Myers Squibb Business Overview Table 32. Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Product Table 33. Bristol-Myers Squibb Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million) Table 34. Bristol-Myers Squibb Recent Development Table 35. Novartis Company Details Table 36. Novartis Business Overview Table 37. Novartis Acute Myeloid Leukemia (AML) Therapeutics Product Table 38. Novartis Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million) Table 39. Novartis Recent Development Table 40. Roche Company Details Table 41. Roche Business Overview Table 42. Roche Acute Myeloid Leukemia (AML) Therapeutics Product Table 43. Roche Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million) Table 44. Roche Recent Development Table 45. Genmab Company Details Table 46. Genmab Business Overview Table 47. Genmab Acute Myeloid Leukemia (AML) Therapeutics Product Table 48. Genmab Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million) Table 49. Genmab Recent Development Table 50. GlaxoSmithKline Pharmaceuticals Company Details Table 51. GlaxoSmithKline Pharmaceuticals Business Overview Table 52. GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Product Table 53. GlaxoSmithKline Pharmaceuticals Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million) Table 54. GlaxoSmithKline Pharmaceuticals Recent Development Table 55. Research Programs/Design for This Report Table 56. Key Data Information from Secondary Sources Table 57. Key Data Information from Primary Sources List of Figures Figure 1. Acute Myeloid Leukemia (AML) Therapeutics Product Picture Figure 2. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size 2017-2028 (US$ Million) Figure 4. United States Acute Myeloid Leukemia (AML) Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States Acute Myeloid Leukemia (AML) Therapeutics Market Size 2017-2028 (US$ Million) Figure 6. United States Acute Myeloid Leukemia (AML) Therapeutics Market Share in Global 2017-2028 Figure 7. Acute Myeloid Leukemia (AML) Therapeutics Report Years Considered Figure 8. Product Picture of Chemotherapy Figure 9. Product Picture of Radiation therapy Figure 10. Product Picture of Stem Cell Transplant Figure 11. Product Picture of Targeted Therapy Figure 12. Product Picture of Others Figure 13. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Type in 2022 & 2028 Figure 14. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2017-2028) & (US$ Million) Figure 15. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Type (2017-2028) Figure 16. United States Acute Myeloid Leukemia (AML) Therapeutics Market Share by Type in 2022 & 2028 Figure 17. United States Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2017-2028) & (US$ Million) Figure 18. United States Acute Myeloid Leukemia (AML) Therapeutics Market Share by Type (2017-2028) Figure 19. Product Picture of Hospital Figure 20. Product Picture of Clinics Figure 21. Product Picture of Others Figure 22. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Application in 2022 & 2028 Figure 23. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2017-2028) & (US$ Million) Figure 24. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Application (2017-2028) Figure 25. United States Acute Myeloid Leukemia (AML) Therapeutics Market Share by Application in 2022 & 2028 Figure 26. United States Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2017-2028) & (US$ Million) Figure 27. United States Acute Myeloid Leukemia (AML) Therapeutics Market Share by Application (2017-2028) Figure 28. North America Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate 2017-2028 (US$ Million) Figure 29. U.S. Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 30. Canada Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 31. Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate 2017-2028 (US$ Million) Figure 32. Germany Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 33. France Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. U.K. Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. Italy Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 36. Russia Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 37. Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate 2017-2028 (US$ Million) Figure 38. China Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. Japan Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. South Korea Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. India Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Australia Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Taiwan Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Indonesia Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Thailand Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 46. Malaysia Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 47. Philippines Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 48. Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate 2017-2028 (US$ Million) Figure 49. Mexico Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 50. Brazil Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 51. Argentina Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 52. Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate 2017-2028 (US$ Million) Figure 53. Turkey Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 54. Saudi Arabia Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 55. UAE Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million) Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) Figure 57. Novartis Revenue Growth Rate in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) Figure 58. Roche Revenue Growth Rate in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) Figure 59. Genmab Revenue Growth Rate in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) Figure 60. GlaxoSmithKline Pharmaceuticals Revenue Growth Rate in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) Figure 61. Bottom-up and Top-down Approaches for This Report Figure 62. Data Triangulation Figure 63. Key Executives Interviewed

Bristol-Myers Squibb Novartis Roche Genmab GlaxoSmithKline Pharmaceuticals